Inhibitors of protein or RNA synthesis prevented prostaglandin (PG) production in isolated skeletal muscles, brain, and spleen. Incubation of rat muscles with cycloheximide prevented the stimulation of PGE2 production induced in vitro by the Ca2+ ionophore A23187 and in vivo by unection of endotoxin. Cycloheximide also inhibited the stimulation by arachidonic acid of PGE2, PGFu, and prostacyclin.
1.14.99.1). These effects were detectable within 10 min after exposure of the muscle to cycloheximnide. The degree of inhibition of PG production correlated with the degree of inhibition of protein synthesis. Other inhibitors of protein synthesis, puromycin and emetine, also prevented conversion of arachidonate into PGE2 in these tissues, but they did not inhibit purified PG synthase. Exposure of muscles to actinomycin D for 20 mI also reduced PGE2 production from arachidonate by 90%. Thus, both the PG synthase and its mRNA appear to be inactivated rapidly (til2 < 10 min) in muscle and other mammalian tissues. The block in PG production induced by inhibitors of protein and RNA synthesis may account for their antipyrogenic actions and certain of their other physiological effects.
Inhibitors of protein synthesis, such as cycloheximide and puromycin, and inhibitors of RNA synthesis, especially actinomycin D, have been widely used to determine whether these processes are necessary for various physiological or cellular adaptations. If a biological response is prevented by such inhibitors, it is inferred that the response itself requires production of a new polypeptide and that other metabolic processes are not affected. In this communication we show that various inhibitors oftranslation and transcription rapidly block the synthesis of prostaglandins (PGs). These metabolites of arachidonic acid participate in a wide variety of pathological and physiological processes, including inflammation, hemostasis, initiation of fever, and the regulation of protein turnover (1) (2) (3) (4) (5) (6) in skeletal muscle. In the course of our studies on the role of PGs in the activation of muscle proteolysis during fever (7, 8) , we observed that muscles treated with cycloheximide synthesized little or no PGE2. Other investigators (9) (10) (11) (12) have noted that prolonged exposure of cultured cells to cycloheximide prevents the rise in PGs induced by platelet-derived growth factor, interleukin 1, or phorbol esters.
The present studies were undertaken to characterize further this unexpected effect of cycloheximide in muscle, to determine whether other metabolites of arachidonic acid and other mammalian tissues are affected similarly, and to explore the mechanism by which inhibitors ofprotein and RNA synthesis may reduce PG production. The present studies indicate that the rate-limiting enzyme in PG production and its mRNA are amongst the most short-lived in mammalian cells and that inhibitors of protein and RNA synthesis may elicit physiological effects indirectly by blocking PG production.
METHODS
Male CD rats (40-50 g), purchased from Charles River Breeding Laboratories, were housed in a temperature-and humidity-controlled environment with a 14-hr light/10-hr dark cycle for 2-4 days before each experiment. Rats were killed by cervical dislocation and the extensor digitorum longus muscles were excised, blotted, and weighed. In some experiments, spleen and brain were dissected out, washed in the incubation buffer, and sliced into four 1-to 3-mm sections. Tissues were incubated at 370C for 30-60 min, then transferred to fresh media (1-2 ml) and incubated at 370C for 1-3 hr as indicated. Incubations were carried out in Krebs-Henseleit buffer (pH 7.4) (13) equilibrated with 02/CO2 (19:1, vol/vol) supplemented with glucose (5 mM), insulin (0.1 unit/ml), leucine (0.85 mM), isoleucine (0.5 mM), and valine (1 mM). After incubation, the tissues were removed, the media were put on ice or frozen at -200C, and the muscles were homogenized in 10%' trichloroacetic acid.
In some experiments [U-_4C]phenylalanine (0.05 mM, 0.1 mCi/mmol; 1 Ci = 37 GBq) was added and rates of protein synthesis were estimated from the amount of phenylalanine incorporated into muscle protein during the incubation as described previously (14) . The muscle homogenates were centrifuged (10 used to bind free [3H]PGs2, and in control studies, these inhibitors of protein and RNA synthesis were found to bind also to the charcoal. PG synthase (EC 1.14.99.1) was purified from ram seminal vesicle microsomes (15) and assayed by L. Marnett. The purified enzyme, which ran as a single band on NaDodSO4/ polyacrylamide gel electrophoresis, exhibited cyclooxygenase and peroxidase activities in the presence of hemin (15) . Arachidonic acid oxidation by the purified PG synthase was determined after a 3-min incubation of the purified enzyme (150 nM) in 0.1 M sodium phosphate (pH 7.8) containing hematin (400 nM) and phenol (500 ,uM), stirred at 370C, in the presence or absence of the inhibitors of protein synthesis ,uM). Assays were performed in triplicate. Arachidonic acid (10 ,uM) was then added, and the initial velocity of oxygen uptake was determined by using a Clark electrode (Yellow Springs Instrument).
Materials. Cycloheximide, puromycin, emetine, and actinomycin D were purchased from Sigma. Porcine insulin was a gift of Eli Lilly. [U-14C]Phenylalanine, [5,6,8,11,12, 14,15- 
RESULTS
Addition of cycloheximide to incubated extensor digitorum longus muscles from normal rats inhibited, almost completely, the basal production of PGE2 (Table 1 , Exp. 1). Skeletal muscles from rats injected with E. coli endotoxin show an enhanced production of PGE2, and this effect is associated with the acceleration of muscle protein breakdown (7, 8) . Values represent the mean ± SEM of eight muscles from eight animals. ND, not detectable. PG production by contralateral extensor digitorum longus muscles was determined during a 2-hr incubation (after a 30-min preincubation) in the presence or absence of 0.25 mM cycloheximide (CX). In Exp. 1, animals were injected intraperitoneally with 0.4 ml of 0.9%o NaCl or E. coli J5 lipopolysaccharide (5 Ag of lipopolysaccharide per 100 g of body weight) 12 hr prior to the experiment (7, 8) . In Exps. 2 and 3, extensor digitorum longus muscles from normal animals were preincubated and incubated with or without the Ca2+ ionophore A23187 (10 ,uM) Synthesis of both PGE2 and PGF2a decreased very rapidly after addition of cycloheximide ( Fig. 1 and data not shown) . When muscles exposed for 30 miin to arachidonic acid (10 ,uM) were transferred to fresh mediuri containing arachidonic acid with or without cycloheximide (0.1 mM), the controls produced PGE2 and PGF2a at a linear rate-for 1 hr, but those exposed to cycloheximide did not synthesize significant amounts ofeither PGE2 or PGF2a (Fig. 1 and data not shown) . In fact, within only 10-20 min after exposure to cycloheximide, production of both PGE2 and PGF2a ceased. In addition, this agent blocked almost completely the synthesis of prostacyclin (PGI2) from arachidonate. This process was determined by measuring the release of the stable metabolite of PGI2, 6-keto-PGF,., which fell by 95% after addition ofcycloheximide (Table   1 ). In addition, cycloheximide prevented any significant rise in PGE2 production above control levels when arachidonic acid was added to stimulate PG12 synthesis. Since the marked fall in production of PGE2, PGF2. and PGk was also observed after addition of arachidonate, the block appears to be at the conversion of arachidonate to PGH2, the common precursor of prostacyclin, thromboxane, and the prostaglandins (16) . These effects of cycloheximide appear similar to those of cyclooxygenase inhibitors-e.g., aspirin and indomethacin (17)-and therefore cycloheximide, either indirectly or. directly, must be blocking the cyclooxygenase and/orthe peroxidase activity (18) of the PG synthase.
To examine whether similar effects ofcycloheximide occur in other tissues as well, we incubated slices of brain and spleen with this agent and measured PG production. In both tissues, cycloheximide almost completely inhibited PGE2 synthesis from arachidonic acid, as was seen in muscle (Table   ,60 Proc. Natl. Acad. Sci. USA 83 (1986) 2773 2). Other investigators have also noted a marked reduction of PGE2 production when protein synthesis was inhibited by cycloheximide in various experimental systems, including dermal fibroblasts stimulated by interleukin 1 (9) or human platelet-derived growth factor (12) and in cultured hepatocytes and kidney cells treated with tumor promoters (10, 11) . Thus, similar effects of cycloheximide seem to occur in a variety of mammalian cells.
To test whether the blockage of PGE2 production was due to the inhibition of protein synthesis or was a specific effect ofcycloheximide on the synthase, we incubated muscles with other inhibitors ofprotein synthesis (Table 3) . Puromycin (50 ,uM) and emetine (50 ,uM) (19) , like cycloheximide, inhibited the incorporation of [tJ-'4C]phenylalanine into muscle proteins by 80-90% and also markedly inhibited the production of PGE2 (by 72-85%) ( Table 3 ). The degree of inhibition of PGE2 production by these agents was thus similar to the percent fall in protein synthesis. Furthermore, lower concentrations of cycloheximide (0.5 AM), which reduced protein synthesis partially (by 57%), caused only a 25% inhibition of PGE2 production (Table 3, Exp. 2). At 0.005 ,M, no significant inhibition of protein synthesis occurred and no effect on PGE2 synthesis was detected.
The similar effects seen with the different inhibitors of protein and RNA synthesis (puromycin, emetine, and cycloheximide), which have quite different structures, makes it unlikely that these compounds act by inhibiting the PG synthase and argue strongly that these agents act by preventing synthesis of this enzyme. Further evidence supporting this conclusion was obtained in muscles treated with emetine, which, unlike cycloheximide, inhibits protein synthesis irreversibly (19) . In muscles extensively washed free of emetine and incubated for an additional 2 hr, protein synthesis was still inhibited by 82% and production ofPGE2 stimulated with the Ca2+ ionophore A23187 was still inhibited by 87% (data not shown).
To test whether inhibitors of protein synthesis influence the PG synthase directly, L. Marnett exposed the enzyme purified from ram seminal vesicle microsomes to these inhibitors and measured the conversion ofarachidonic acid to PGH2. Addition of these inhibitors to the purified PG synthase had no effect on the ability of this enzyme to oxidize arachidonic acid. In control incubations, the initial rate of arachidonic acid oxidation was 182 ± per min with 50 ,tM puromycin, and 171 ± 9 ,uM 02 per min with 50 AM cycloheximide added. Under the same conditions, the PG synthase inhibitor indomethacin (3 ,uM) abolished oxygen uptake. Thus, inhibitors of protein synthesis do not act as simple inhibitors of the PG synthase. It is therefore likely that the PG synthase is subject to rapid turnover, and, in the absence of continued protein synthesis, this enzymatic activity is lost very rapidly through irreversible inactivation, proteolytic degradation, or both. Physiological Sciences: Fagan and Goldbe 'rg Because of these large effects of protein synthesis inhibitors, we tested whether an inhibitor of RNA synthesis, actinomycin D (20) , also inhibited PGE2 production in muscle. The addition of actinomycin D (10 ;LM) to both the preincubation and incubation medium reduced PGE2 synthesis by 93% in the isolated rat extensor digitorum longus muscles (Table 3 ,uM) did not affect the activity of the purified PG synthase (data not shown). Thus, this agent, like cycloheximide, puromycin, and emetine, seems to affect the PG synthase step. With time, exposure to actinomycin D causes an increasing inhibition of protein synthesis (21) , presumably because of the loss of more short-lived mRNA under these conditions. PG synthase activity decreased almost completely within the first hour, even though by the second hour overall protein synthesis had fallen by only 28%. Thus inhibition of transcription with actinomycin D seems to inhibit differentially the synthesis of this enzyme. Therefore, the mRNA for the PG synthase, like the enzyme activity, appears to be very short-lived. In fact, the 90% loss of enzyme activity within 10-20 min after addition of actinomycin D (Fig. 1) would suggest an mRNA half-life ofless than 10 min.
DISCUSSION
The finding that inhibitors of protein and RNA synthesis can rapidly block the production of PG may influence the interpretation of various biological experiments using these inhibitors. These concerns are especially important when investigating physiological responses in which metabolites of arachidonic acid are known to play a role. For example, the initiation of fever involves production of PGE2 from arachidonate in the hypothalamus (22) . It has been reported that cycloheximide and actinomycin D can reduce fever in human patients with Hodgkin disease and other malignancies (23) and that cycloheximide and other inhibitors of protein synthesis inhibit fever in animals injected with viruses or endogenous pyrogen (22) (23) (24) (25) (26) (27) . These effects on body temperature thus resemble those seen with cyclooxygenase inhibitors (e.g., aspirin and indomethacin). Furthermore, other unexplained effects of these inhibitors [e.g., their ability to influence rates of protein breakdown under certain conditions (28) ] may also result from the fall in PGs or thromboxane or indirectly from increased production of other metabolites of arachidonic acid due to the block in the cyclooxygenase pathway (e.g., leukotrienes).
Our findings indicate that inhibitors of transcription and translation prevent production of PGE2 by causing a block at the PG synthase step. This enzyme, which displays both cyclooxygenase and peroxidase activities, is responsible for the conversion of arachidonate to PGG2 and PGH2, the common precursor for prostacyclin, thromboxane, and the prostaglandins. Effects on later enzymatic steps could not account for the simultaneous fall in PGE2, PGF2a, and PGI2 from arachidonate. The results presented here cannot be explained by rapid turnover of the phospholipase as has been suggested (10) . Inhibition at the PG synthase step has also been noted recently by Habenicht et al. (12) in fibroblasts and Daniel et al. (11) in kidney cells. Nevertheless, it is possible that other enzymes in this pathway, in addition to the PG synthase, are also affected (see below).
Of particular interest is the rapidity by which the inhibitors of protein and RNA synthesis block the production of PGs. Exposure to cycloheximide and actinomycin D for as little as 10-20 min prevented almost completely the subsequent production of PGE2 from arachidonate in muscle. These various inhibitors seem to prevent synthesis of the PG synthase and do not influence its activity directly when added to the purified enzyme. Therefore, as shown in Fig. 1 (11, 12, (36) (37) (38) (39) (40) (41) .
It remains to be established whether the PG synthase undergoes irreversible inactivation, complete degradation, or both after inhibition of its synthesis. In cell extracts, a rapid irreversible autoinactivation of the PG synthase (42) has been reported for both the cyclooxygenase (43, 44) and the peroxidase (45, 46) activity. The enzyme is thought to be inactivated by oxidants that are released during the enzymatic reduction of the hydroperoxide on PGG2 (45, 46) , and the enzyme could be protected in extracts by agents that scavenge oxygen radicals (44) (45) (46) (47) (48) (49) . The oxidant responsible for the inactivation of the prostaglandin synthase was also found to inactivate the PGI2 synthase (50, 51) as well as a variety of other enzymes (52) . Presumably, this irreversible inactivation seen in extracts also occurs in vivo; therefore continuous replacement of the PG synthase by de novo synthesis would be necessary. Although autoinactivation of the enzyme cannot explain the rapid loss of its mRNA, such a mechanism would account nicely for the rapid disappearance of the enzyme activity after protein synthesis was blocked.
